Opinion|Videos|September 3, 2024
ASCERTAIN Data: Oral Decitabine-Cedazuridine Outcomes in MDS
Medical experts discuss the data gathered from the ASCERTAIN trial.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- Although oral decitabine-cedazuridine has been FDA approved for some time, the ASCERTAIN trial data are a recent advancement in our knowledge of this drug and its use in myelodysplastic syndromes (MDS). Briefly describe the ASCERTAIN trial design.
- What are some key takeaways regarding the outcomes of treating MDS with oral decitabine-cedazuridine compared with intravenous decitabine, according to the ASCERTAIN data?
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Advertisement
Advertisement
Trending on AJMC
1
Health Insurance CEOs Questioned by House Committee About Rising Costs in Health Care
2
Semaglutide Shows Promise for Steatohepatitis Resolution in MASH
3
Advancing Biomarker Testing Across GU, Lung, and Myeloma Care
4
Socioeconomic Factors Linked to Surgical Outcomes in Upper Extremity Soft Tissue Sarcoma
5
